Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy and the efficacy of combined therapy with PD‐1 inhibitor plus cytotoxic chemotherapy as first‐line treatment has not previously been clarified. The gene discussed is PDCD1; the disease is lung carcinoma.